Company intelligence / Profile preview

BlueDot

Toronto, Ontario, Canadabluedot.global ↗

Ownership: Private
Development stage: Commercial

Overview

BlueDot provides real-time global infectious disease surveillance and risk assessment using artificial intelligence and expert analysis. Its platform has been used to predict outbreaks such as Ebola and Zika, and it was the first to detect the COVID‑19 outbreak in Wuhan before WHO alerts. The company’s tools are trusted by governments and enterprises worldwide for pandemic preparedness and response. No clinical results as it does not develop drugs or biologics.

Therapeutic areas: Infectious Diseases
Industry: Biomedical IT and Biomedical Data Platforms

Partnerships

Public Health Agency of CanadaVarious governments worldwide

Beyond the preview

Go deeper on BlueDot.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BlueDot.

Explore the full profile